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thought to contribute to chronic pain. In inflammatory pain, reductions in synaptic inhibition occur
partially through prostaglandin E2- (PGE2-) and PKA-dependent phosphorylation of a specific subtype
of glycine receptors (GlyRs) that contain ￿3 subunits. Here, we demonstrated that 2,6-di-tert-butylphenol
(2,6-DTBP), a nonanesthetic propofol derivative, reverses inflammation-mediated disinhibition through
a specific interaction with heteromeric ￿￿GlyRs containing phosphorylated ￿3 subunits. We expressed
mutant GlyRs in HEK293T cells, and electrophysiological analyses of these receptors showed that 2,6-
DTBP interacted with a conserved phenylalanine residue in the membrane-associated stretch between
transmembrane regions 3 and 4 of the GlyR ￿3 subunit. In native murine spinal cord tissue, 2,6-DTBP
modulated synaptic, presumably ￿￿ heteromeric, GlyRs only after priming with PGE2. This observation
is consistent with results obtained from molecular modeling of the ￿-￿ subunit interface and suggests
that in ￿3￿GlyRs, the binding site is accessible to 2,6-DTBP only after PKA-dependent phosphorylation.
In murine models of inflammatory pain, 2,6-DTBP reduced inflammatory hyperalgesia in an ￿3GlyR-
dependent manner. Together, our data thus establish that selective potentiation of GlyR function is
a promising strategy against chronic inflammatory pain and that, to our knowledge, 2,6-DTBP has a
unique pharmacological profile that favors an interaction with GlyRs that have been primed by peripheral
inflammation.
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Introduction
Chronic pain states are associated with complex molecular and 
cellular changes in the peripheral and central nervous system (1–3). 
An increasing body of evidence indicates that diminished inhibi-
tory GABAergic and glycinergic neurotransmission at the level of 
the spinal dorsal horn makes an important contribution to chronic 
pain states (2, 4, 5). A variety of mechanisms have been identified 
that differentially contribute to diminished synaptic inhibition in 
various inflammatory and neuropathic pain states (1, 2). In the 
case of inflammatory pain, a reduction in glycinergic inhibition 
occurring through PGE2- and PKA-dependent phosphorylation of 
a specific subtype of glycine receptors (GlyRs; i.e., those contain-
ing the α3 subunit [α3GlyR]) has a major role (6). Restoring the 
activity of the synaptic α3GlyR through positive allosteric modu-
lators may therefore constitute a mechanism-based therapeutic 
approach against chronic inflammatory pain.
Despite the importance of GlyRs in a variety of physiological 
processes, GlyR pharmacology is still poorly developed, and only a 
few GlyR modulators are available at present (7–9). Some of these 
compounds, such as several propofol derivatives, modulate GlyRs 
at nanomolar or even subnanomolar concentrations (10, 11), but 
none of them are fully specific for GlyRs and many of them also 
modulate the function of other ion channels (8). This lack of speci-
ficity has hampered establishing causal links between molecular 
and therapeutic actions (12–15).
Using molecular, electrophysiological, and behavioral 
approaches, we explored the basis of GlyR allosteric modulation 
by the nonanesthetic propofol derivative 2,6-di-tert-butylphenol 
(2,6-DTBP). 2,6-DTBP potentiates currents through recombi-
nant α1GlyRs (16) but has negligible activity at GABAA receptors 
(GABAARs) (17, 18). Here, we show that 2,6-DTBP is a positive 
α3GlyR allosteric modulator that effectively restores the loss of 
α3GlyR-mediated inhibition in inflammatory pain states, at least 
partially through a selective potentiation of phosphorylated GlyRs 
containing α3 and β subunits. A specific phenylalanine residue in 
the α3 subunit appears to be critical for this potentiation. Thus, our 
results establish a potentially novel mechanism for pharmacologi-
cal intervention against inflammatory pain through phosphoryla-
tion-specific potentiation of the spinal α3GlyR.
Results
Conformation-specific potentiation of recombinant α3GlyR by 2,6-
DTBP. We first assessed the effects of 2,6-DTBP on glycine-evoked 
currents through recombinant GlyRs expressed in HEK293T cells 
(for glycine response parameters of all GlyR variants tested in this 
study, see Supplemental Table 1; supplemental material avail-
able online with this article; doi:10.1172/JCI83817DS1). Homo-
pentameric α3GlyRs were strongly potentiated by micromolar 
concentrations of 2,6-DTBP (Figure 1, A and B). The efficacy of 
Diminished inhibitory neurotransmission in the superficial dorsal horn of the spinal cord is thought to contribute to 
chronic pain. In inflammatory pain, reductions in synaptic inhibition occur partially through prostaglandin E2- (PGE2-) and 
PKA-dependent phosphorylation of a specific subtype of glycine receptors (GlyRs) that contain α3 subunits. Here, we 
demonstrated that 2,6-di-tert-butylphenol (2,6-DTBP), a nonanesthetic propofol derivative, reverses inflammation-mediated 
disinhibition through a specific interaction with heteromeric αβGlyRs containing phosphorylated α3 subunits. We expressed 
mutant GlyRs in HEK293T cells, and electrophysiological analyses of these receptors showed that 2,6-DTBP interacted with 
a conserved phenylalanine residue in the membrane-associated stretch between transmembrane regions 3 and 4 of the GlyR 
α3 subunit. In native murine spinal cord tissue, 2,6-DTBP modulated synaptic, presumably αβ heteromeric, GlyRs only after 
priming with PGE2. This observation is consistent with results obtained from molecular modeling of the α-β subunit interface 
and suggests that in α3βGlyRs, the binding site is accessible to 2,6-DTBP only after PKA-dependent phosphorylation. In 
murine models of inflammatory pain, 2,6-DTBP reduced inflammatory hyperalgesia in an α3GlyR-dependent manner. 
Together, our data thus establish that selective potentiation of GlyR function is a promising strategy against chronic 
inflammatory pain and that, to our knowledge, 2,6-DTBP has a unique pharmacological profile that favors an interaction with 
GlyRs that have been primed by peripheral inflammation.
Phosphorylation state–dependent modulation of 
spinal glycine receptors alleviates inflammatory pain
Mario A. Acuña,1,2 Gonzalo E. Yévenes,1,3 William T. Ralvenius,1,2 Dietmar Benke,1,2,4 Alessandra Di Lio,1,2 Cesar O. Lara,3  
Braulio Muñoz,3 Carlos F. Burgos,3 Gustavo Moraga-Cid,3,5 Pierre-Jean Corringer,5 and Hanns Ulrich Zeilhofer1,2,4,6
1Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. 2Neuroscience Center Zurich, Zurich, Switzerland. 3Department of Physiology, Faculty of Biological Sciences,  
University of Concepcion, Concepcion, Chile. 4Drug Discovery Network Zurich, Zurich, Switzerland. 5Channel-Receptors Unit, Institute Pasteur, Paris, France.  
6Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.
Authorship note: M.A. Acuña and G.E. Yévenes contributed equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: July 17, 2015; Accepted: April 14, 2016.
Reference information: J Clin Invest. 2016;126(7):2547–2560. doi:10.1172/JCI83817.
Downloaded from http://www.jci.org on July 15, 2016.   http://dx.doi.org/10.1172/JCI83817
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
2 5 4 8 jci.org   Volume 126   Number 7   July 2016
Figure 1. Modulation of recombinant GlyRs by 2,6-DTBP in HEK293T cells. (A) Example whole-cell current traces evoked by glycine (EC10) in the absence or 
presence of 2,6-DTBP (100 μM) in homomeric α3 or α1GlyRs, and in heteromeric α3β or α1βGlyRs. (B) Concentration-response curves of 2,6-DTBP obtained 
with an EC10 of glycine in homomeric α3 or α1GlyRs, and in heteromeric α3β or α1βGlyRs. (C) Heteromeric α3/β and α1/βGlyRs are significantly less suscep-
tible to modulation by 2,6-DTBP than homomeric α1 and α3GlyRs. **P < 0.01, unpaired t test. (D) Concentration-response curves of glycine for the homo-
meric α3GlyR in the absence or in the presence of 2,6-DTBP (100 μM, red). (E) Single-channel current traces recorded from membranes expressing α3GlyRs 
in the presence and the absence of 2,6-DTBP (10 μM). (F) 2,6-DTBP increases ion channel open probability (nPo) but not single-channel main conductance. 
**P < 0.01, paired t test. Data are the mean ± SEM from 6 to 10 cells (B–D) or 6 patches per group (F).
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figuration (19) showed that 2,6-DTBP significantly increased the 
ion channel open probability (nPo) (control nPo = 0.20 ± 0.02 
versus 2,6-DTBP nPo = 0.58 ± 0.10, paired t test, P < 0.01, Figure 
1, E and F, and Supplemental Table 2) without apparent changes 
in the main conductance levels (control γ = 91.0 ± 1.20 pS versus 
2,6-DTBP γ = 90.1 ± 0.92 pS, paired t test, Figure 1, E and F, and 
Supplemental Table 2).
In order to explore the molecular determinants of α3GlyR 
modulation by 2,6-DTBP, we first focused on molecular sites in 
α1GlyR and α3GlyR involved in the modulation by propofol, the 
parent compound of 2,6-DTBP. Previous analyses of structure-
activity relationships have identified S267 in TM2, A288 in TM3, 
and F380 in the interface between the intracellular region and the 
TM4 domain as critical for the modulation of the α1GlyR by pro-
pofol (20–22). All three residues are conserved between α1GlyR 
and α3GlyR. Other studies have, however, found that mutation of 
two of these residues (S267 and A288) also severely interferes with 
GlyR function itself (23, 24). By contrast, mutation of F380 dimin-
ished propofol sensitivity without altering ion channel gating and 
conductance (21). We therefore examined whether the mutation 
of phenylalanine to alanine in position 388 (F388A) would affect 
the sensitivity of the α3GlyR to 2,6-DTBP. Whole-cell recordings 
revealed that the F388A mutation did not change the sensitivity 
potentiation by 2,6-DTBP (determined at a 2,6-DTBP concentra-
tion of 100 μM and at the EC10 of glycine) was higher for α3GlyRs 
than for α1GlyRs (211% ± 30% versus 115% ± 19%, P < 0.05, n = 6, 
unpaired t test). We next assessed the modulation of heteromeric 
αβGlyRs (as these receptors constitute most GlyRs at postsynaptic 
sites). The efficient expression of heteromeric GlyRs containing 
both α and β subunits was confirmed by their relative insensitivity 
to picrotoxin (PTX), which blocks homomeric GlyRs with higher 
potency than αβ heteromeric receptors (Supplemental Figure 1). 
Compared with homomeric GlyRs, potentiation of heteromeric 
α3β or α1βGlyRs was significantly weaker (20% ± 10% and 30% 
± 6% for α3β and α1βGlyRs, respectively, Figure 1, A–C). We then 
evaluated the biophysical mechanisms underlying the alloste-
ric modulation by 2,6-DTBP of α3GlyRs. Whole-cell recordings 
showed that 2,6-DTBP caused a leftward shift in the glycine con-
centration-response curve of the α3GlyR. The EC50 values were 
206 ± 1.0 μM and 76 ± 2.3 μM, under control conditions and in the 
presence of 100 μM 2,6-DTBP, respectively (P < 0.001, unpaired t 
test) (Figure 1D), suggesting an increase in the apparent affinity of 
the receptor for its agonist. 2,6-DTBP did not affect the maximal 
current amplitude elicited by 1 mM glycine (5.0 ± 1.0 nA versus 
4.8 ± 1.1 nA, in the presence and absence of 100 μM 2,6-DTBP, 
respectively). Single-channel recordings in the cell-attached con-
Figure 2. A molecular site for the actions of 2,6-DTBP on α3GlyRs. (A) Concentration-response curves of glycine in wild-type and (F388A) point-mutated 
α3GlyRs. (B) Traces of glycine-activated whole-cell currents recorded from cells expressing wild-type or (F388A) point-mutated α3GlyRs in the absence 
or presence of 2,6-DTBP (100 μM). (C) Concentration-response curves of 2,6-DTBP for wild-type and (F388A) point-mutated α3GlyRs. (D) Examples of 
single-channel recordings from membranes expressing point-mutated (F388A) α3GlyRs in the presence or absence of 2,6-DTBP. (E) Ion channel nPo of 
the (F388A) α3GlyR in the absence or presence of 2,6-DTBP (10 μM). (F) Percentage change of nPo following the application of 2,6-DTBP in wild-type and 
(F388A) point-mutated α3GlyRs. ***P < 0.001, unpaired t test. All data are the mean ± SEM from 6 to 9 cells per group.
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Figure 3. Influence of S346 phosphomutation in α3GlyR on allosteric modulation by 2,6-DTBP. (A) Localization of the S346 residue in the primary sequence 
of the mouse GlyR α3 subunit, the corresponding sequence in the GlyR α1 subunit, and schematic diagram illustrating this site in the α3GlyR topology. (B) 
Proximity ligation assay (PLA) demonstrating phosphorylation of α3GlyR by PGE2 (1 μM) in HEK293T cells transfected with the EP2 receptor and wild-type 
GlyR α3 or (S346A) point-mutated GlyR α3 subunit plasmids. Top: α3GlyR immunofluorescence, bottom: PLA signal. Scale bar: 5 μm. (C) PGE2 significantly 
increased PLA signals in HEK293T cells transfected with wild-type but not with (S346A) GlyR α3 subunits. ***P < 0.001, ANOVA followed by Bonferroni 
post-hoc test, F(2,141) = 49.84; P < 0.001, PGE2 in wild-type α3GlyR-transfected cells versus the other two conditions. (D) Example traces of glycine-activated 
currents in α3(S346A)β or α3(S346E)βGlyRs in the absence and presence of 2,6-DTBP (100 μM). (E) Concentration-response curves for 2,6-DTBP in homomeric 
α3 (left) and heteromeric α3βGlyRs (right) containing S346E or S346A mutations. (F) The phosphomimicking S346E mutation restored 2,6-DTBP sensitivity of 
α3βGlyRs but had little effect on that of homomeric α3GlyRs. **P < 0.01, unpaired t test. (G) The F388A point mutation in α3GlyRs abolished 2,6-DTBP sensi-
tivity. Introducing the S346E mutation did not restore 2,6-DTBP sensitivity in homomeric α3(F388A)GlyRs or heteromeric α3(F388A)βGlyRs. **P < 0.01, ***P < 
0.001, ANOVA followed by Bonferroni post-hoc test, F(3,35) = 20.7 (left) and F(2,16) = 8.81 (right). (H) Structural model of the α3GlyR. Left: location of the F388 
residue (red) and of 2,6-DTBP (yellow sphere) in a homopentameric α3GlyR. Other relevant residues are shown in magenta (P381 and M384) and blue (D382 
and R385). Top, right: view from the middle of the plasma membrane on the putative acceptor sites with 2,6-DTBP bound (in yellow spheres) within a penta-
meric complex. Bottom, right: detailed view of the putative acceptor site of 2,6-DTBP. The hydrophobic interaction supported by F388 is highlighted in red.
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in inflammation-induced inhibition of synaptic GlyR currents in 
the superficial spinal dorsal horn (ref. 6 and Figure 3A; note that 
the GlyR α1 subunit lacks this consensus site). In order to provide 
direct evidence for PKA-dependent phosphorylation of S346 in 
GlyR α3, we made use of the in situ proximity ligation assay (in situ 
PLA, ref. 26). Incubation of HEK293T cells transiently transfected 
with wild-type GlyR α3 subunits and EP2 receptors led to a signifi-
cant increase in the phosphorylation-dependent PLA signal after 
exposure to PGE2 (1 μM). This increase was absent in point-mutat-
ed GlyR α3(S346A) (Figure 3, B and C). To explore a potential inter-
action between phosphorylation at S346 and α3GlyR modulation 
by 2,6-DTBP, we investigated the impact of S346 phosphorylation 
on the α3GlyR function and modulation and tested two point-
mutated receptors that mimic the phosphorylated (S346E) and 
nonphosphorylated (S346A) state. Electrophysiological record-
ings revealed that the phosphorylation state did not affect the 
sensitivity of homomeric or heteromeric α3GlyRs to their natural 
agonist glycine (Supplemental Figure 2 and Supplemental Table 
1). Likewise, homomeric GlyRs composed of GlyR α3(S346A) or 
GlyR α3(S346E) did not appreciably differ in their sensitivities to 
2,6-DTBP (142% ± 23% in S346A versus 190% ± 42% in S346E, 
100 μM 2,6-DTBP, Figure 3, D–F). However, heteromeric GlyRs 
containing the phosphomimicking S346E mutation were sig-
nificantly more sensitive to 2,6-DTBP than those containing the 
of the homomeric α3GlyR to glycine (Figure 2A), but significantly 
impaired sensitivity to 2,6-DTBP. At 100 μM, 2,6-DTBP potenti-
ated the wild-type α3GlyR by 164% ± 20% (n = 12), whereas poten-
tiation of the F388A α3GlyR only reached 10% ± 9.0% (n = 10) 
(Figure 2, B and C). To gain additional molecular insight, we ana-
lyzed the effects of 2,6-DTBP in single-channel recordings of the 
α3GlyR carrying the F388A mutation. 2,6-DTBP (10 μM) did not 
significantly modify the activity of F388A mutant ion channels 
(control nPo = 0.18 ± 0.05 versus 2,6-DTBP nPo = 0.19 ± 0.04, 
paired t test), confirming the low sensitivity of the mutated recep-
tor to modulation by 2,6-DTBP (wild-type = 192.8% ± 32.6% of 
nPo increase above control versus F388A = 5.7% ± 15.6%, unpaired 
t test, P < 0.001, Figure 2, D–F, and Supplemental Table 2). Addi-
tional analyses revealed that wild-type and F388A mutant GlyR α3 
exhibited similar conductance levels (wild-type γ = 91.0 ± 1.20 pS 
versus F388A γ = 88.2 ± 1.82 pS, P = 0.44, unpaired t test). These 
results confirm that the F388A mutation diminished the sensitivity 
of α3GlyRs to 2,6-DTBP without altering the ion channel function.
A molecular site for the actions of 2,6-DTBP on the α3GlyR. The 
F388 residue required for modulation by 2,6-DTBP lies within 
the so-called membrane-associated (MA) stretch of the channel 
immediately upstream of the transmembrane region 4 (25). This 
site is close to a consensus site for PKA-dependent phosphoryla-
tion of GlyR α3 (serine 346) that has been previously implicated 
Figure 4. 2,6-DTBP has no significant effects on evoked glycinergic and GABAergic neurotransmission in naive superficial dorsal horn neurons. (A–C) 
Effects of 2,6-DTBP (100 μM) on amplitudes (mean ± SEM) (A) or decay time constants (B) of light-evoked Gly-IPSCs. Inset, example glycinergic IPSC traces 
averaged from 10 consecutive current traces (A) or scaled traces (B). Black, control (CTRL) condition; red, 2,6-DTBP. (C) Paired t test, P = 0.12 and P = 0.28, 
for amplitudes and decay time constants, respectively, n = 6. (D–F) Same as (A–C) but GABA-IPSCs. (F) Paired t test, P = 0.47 and P = 0.37 for amplitudes 
and decay time constants, respectively, n = 6.
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S346A mutation (S346A: 10% ± 8% versus S346E: 112% ± 31%, 
100 μM 2,6-DTBP, P < 0.01, unpaired t test). These results dem-
onstrate that the heteromeric phosphorylated α3βGlyRs are more 
sensitive to modulation by 2,6-DTBP, indicating a conformation-
selective modulation of α3βGlyRs. We then examined whether the 
mutation of F388 could affect the 2,6-DTBP sensitivity of phos-
phorylated α3GlyR. To this end, we studied double point-mutated 
α3GlyRs containing both the S346E and the F388A mutation. 
The F388A mutation significantly attenuated the potentiation of 
homomeric α3(S346E) GlyRs and heteromeric α3(S346E)β GlyRs 
Figure 5. Pretreatment with PGE2 renders synaptic α3βGlyRs susceptible to modulation by 2,6-DTBP. (A) Normalized amplitudes (mean ± SEM) (top 
panel) and decay time constants (bottom panel) of light-evoked Gly-IPSC traces versus time, before and during the application of PGE2 (1 μM) and in 
the additional presence of 2,6-DTBP (100 μM). Insets are example traces averaged from 10 consecutive stimulations under the three conditions (n = 12). 
(B) Same as (A) but preincubated with H-89 (5 μM) to prevent phosphorylation of GlyRs by PGE2 (n = 7). (C) Same as (A) but experiments done in slices 
taken from GlyRα3–/– mice. In these experiments, Gly-IPSCs were evoked by electrical field stimulation, n = 12. (D) Left panel: PGE2 reduced Gly-IPSC 
amplitudes in control slices but not in H89-treated slices or in slices from GlyRα3–/– mice, while 2,6-DTBP had no significant effects on Gly-IPSC ampli-
tudes in either condition. **P = 0.01, significant versus control (CTRL). ANOVA followed by Bonferroni post-hoc test. F(2,35) = 8.58, F(2,18) = 1.76, and 
F(2,30) = 0.12 for Gly-IPSC amplitudes shown in A–C, respectively. Right panel: 2,6-DTBP significantly prolonged Gly-IPSC decay time courses in PGE2-
treated wild-type slices, but not in slices pretreated with H89, or in slices prepared from GlyRα3–/– mice. ANOVA followed by Bonferroni post-hoc test. 
†††P < 0.001,  significant versus PGE2; ***P < 0.001 significant versus control. F(2,35) = 15.66, F(2,18) = 0.20, and F(2,30) = 0.62 for experiments shown in 
A–C, respectively. n = 7–12 cells per group. All scale bars: 50 ms, 400 pA.
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(Figure 3G). These data indicate that the F388 residue is critical 
for the potentiation of both homomeric α3 and heteromeric (phos-
phorylated) α3βGlyRs.
Given the key role of F388 in the effects of 2,6-DTBP on the 
α3GlyR, we next asked whether this residue could be a critical part 
of an acceptor site for 2,6-DTBP. To this end, we developed a mod-
el of the α3GlyR based on the crystal structures of GluCl and GLIC-
GlyR (27, 28). The results of this modeling were not only consistent 
with F388 being located in the MA stretch close to transmembrane 
segment 4 (Figure 3H), but also provided insights into the molecu-
lar composition of the putative acceptor site for 2,6-DTBP. Three 
residues (F388, M384, and P381) appeared to be particularly rele-
vant for hydrophobic interactions between 2,6-DTBP and α3GlyRs. 
The charged residues D382 and R385 complement the binding 
area. Molecular docking analyses revealed a favorable theoreti-
cal energy of interaction with this putative acceptor site (ΔGbind = 
–42.09 kcal/mol, docking score = –2.133). The energy of interac-
tion and the docking scores of 2,6-DTBP and of other propofol 
analogs with this molecular site correlate well with the functional 
modulation of wild-type α3GlyRs (Supplemental Table 3). Interest-
ingly, our modeling data suggest that the introduction of the F388A 
mutation causes a significant decrease in these parameters (ΔGbind 
= –29.51 kcal/mol, docking score = –0.507), suggesting a direct rela-
tionship between the degree of potentiation of the α3GlyR by 2,6-
DTBP and the energy of interaction. Additional molecular model-
ing and simulations suggest that the GlyR β subunit also displayed 
a lower energy of interaction with 2,6-DTBP (ΔGbind = –27.99 kcal/
mol, docking score = 0.194), possibly because of the presence of 
an isoleucine at position 388 (i.e., I443 in the β subunit) and a poor 
structural homology with the α subunits in these particular regions 
(Supplemental Figure 3). Overall, these results identified F388 as a 
pivotal residue for the effects of 2,6-DTBP on the α3GlyR and sug-
gest the presence of a 2,6-DTBP acceptor site in the MA stretch of 
α3 that is not present within the β subunit.
Modulation of Gly-IPSCs by 2,6-DTBP in superficial dorsal horn 
neurons. We next characterized the effects of 2,6-DTBP on native 
GlyRs in excitatory lamina II dorsal horn neurons, i.e., at a site that 
serves a pivotal role in pain control and which expresses a high 
density of α3GlyRs (6). To this end, we prepared lumbar spinal cord 
slices from VGAT::ChR2 BAC transgenic mice (29), which permit 
selective activation of inhibitory neurons through short pulses of 
blue light (30). In slices taken from these mice, excitatory neurons 
can be readily identified by the absence of a photocurrent (for 
details see Methods and ref. 30). Of a total of 256 lamina II dor-
sal horn neurons, 121 were photocurrent negative and hence pre-
sumably excitatory. Wide-field stimulation with blue light elicited 
inhibitory postsynaptic current (IPSC) responses in all these cells. 
Bicuculline (10 μM) or strychnine (1 μM) was used to isolate gly-
cinergic or GABAergic IPSCs (Gly-IPSCs or GABA-IPSCs), respec-
tively. We then analyzed the effect of 2,6-DTBP (100 μM) on the 
amplitudes and decay time constants of light-evoked Gly-IPSCs 
and GABA-IPSCs (Figure 4). As expected from the experiments 
with recombinant GlyRs, 2,6-DTBP had no significant effect on 
Gly-IPSCs under basal conditions. Gly-IPSC amplitudes slightly 
decreased 8.6% ± 3.1% relative to control values (n = 8, P = 0.09, 
paired t test), while rise time and decay time slightly increased 13% 
± 9% and 14% ± 9%, respectively (P = 0.50 and P = 0.17, paired t 
test) (Figure 4, A–C). Likewise, light-evoked GABA-IPSCs were 
not significantly affected (–6.1% ± 7.3%; P = 0.57, and 1.1% ± 9.6%; 
P = 0.92, for amplitudes and decay time constants, respectively, 
n = 6) (Figure 4, D–F). It is likely that most of the receptors under-
lying these synaptic currents were heteromeric receptors contain-
ing α1 and/or α3 subunits together with β subunits (6). To address 
a potential effect on extrasynaptic receptors, we analyzed whether 
2,6-DTBP would modulate tonic GlyR currents. In agreement with 
previous results (31), these experiments revealed the presence of 
small-amplitude tonic currents (Itonic = 3.2 ± 1.0 pA) in only a small 
fraction of the superficial dorsal horn neurons (4 of 14). These ton-
ic currents were not significantly changed by 100 μM 2,6-DTBP 
(+4.6% ± 7.6% versus control amplitudes, P = 0.56, paired t test, 
Supplemental Figure 4). The present results indicate that, in slices 
taken from naive mice, neither synaptic nor extrasynaptic GlyRs 
were susceptible to significant modulation by 2,6-DTBP.
Since our data obtained in recombinant GlyRs have shown 
that the phosphorylation of the α3 subunit at S346 increases the 
sensitivity of α3βGlyRs to 2,6-DTBP (compare Figure 3, D–F), we 
Figure 6. Effects of 2,6-DTBP on the amplitude and decay time of Gly-IPSCs recorded from lamina II neurons of mice with inflamed hindpaws. Record-
ings were made from the dorsal horn neurons ipsilateral to the inflamed paw. (A) Normalized Gly-IPSC amplitudes over time of whole-cell recording. (B) 
Same as (A) but normalized decay time constant. (C) 2,6-DTBP had no significant effect on IPSC amplitudes, but significantly increased the decay time 
constant. **P < 0.01, paired t test, n = 6 cells.
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35% ± 5% relative to control amplitudes, P < 0.001, n = 12, paired t 
test) but did not change their rise or decay time kinetics (rise time: 
–0.2% ± 8% versus control, decay time: +6% ± 7% versus control, 
P = 0.99 and P = 0.23, paired t test, n = 12) (Figure 5, A and D). 
Subsequent application of 2,6-DTBP significantly increased the 
decay time constant of Gly-IPSCs by 54% ± 11% (P < 0.001, n = 12, 
hypothesized that glycinergic synapses containing the α3 subunit 
might be more sensitive to 2,6-DTBP under inflammatory condi-
tions, i.e., in a phosphorylated state. We therefore assessed the 
effects of 2,6-DTBP on Gly-IPSCs after preconditioning of the 
slices with PGE2 (Figure 5). Superfusion of the slices with PGE2 
(1 μM) significantly reduced the amplitude of the Gly-IPSC (by 
Figure 7. In vivo antihyperalgesic effects of 2,6-DTBP. (A 
and B) Zymosan A model of inflammatory hyperalgesia. 
Zymosan A (0.06 mg) was injected subcutaneously into 
one hindpaw. 2,6-DTBP (90 mg/kg i.p.) or vehicle (VEH) 
was administered 48 hours after zymosan A. (A) Mechani-
cal hyperalgesia. Treatment × time interactions (P < 0.05) 
were significant for time points between 30 minutes 
and 2 hours [2-way repeated measures ANOVA, F(1,6) 
values ranging from 5.0 to 8.2]. Right: maximum possible 
antihyperalgesic effects (MPE) determined for the interval 
30 to 60 minutes after 2,6-DTBP injection. *P < 0.05, 
unpaired t test, n = 6 and 7 mice for 2,6-DTPB and vehicle, 
respectively. (B) Same as (A), but heat hyperalgesia. Treat-
ment × time interactions were significant for time points 
between 30 minutes and 4 hours [F(1,6) = 7.2 to 24.8]. 
MPEs: Unpaired t test, **P < 0.01, n = 7 and 6. (C) Inflam-
matory hyperalgesia evoked by CFA. 2,6-DTBP was applied 
2 days after CFA injection. In wild-type mice (n = 7 and 9), 
treatment × time interactions were significant (P < 0.05) 
for time points between 30 minutes and 4 hours [F(1,6) = 
4.8 to 20.0]. In GlyRα3–/– mice (n = 10 and 7), interactions 
remained insignificant for all time points [P > 0.17; F(1,6) 
= 0.02 to 0.7]. Significant MPE of 2,6-DTBP (determined 
between 60 and 90 minutes) were found in wild-type, 
but not in GlyRα3–/– mice. The MPE differed significantly 
between wild-type and GlyRα3–/– mice [ANOVA followed 
by Bonferroni post-hoc test, F(3,38) = 9.97; ***P < 0.001, 
for vehicle versus 2,6-DTBP in wild-type mice]; ††P < 0.01 
(2,6-DTBP effect in wild-type versus GlyRα3–/– mice). (D) 
Neuropathic hyperalgesia. 2,6-DTBP was applied 7 days 
after CCI. In wild-type mice, treatment × time interac-
tions were significant (P < 0.05) between 30 minutes and 
90 minutes [F(1,6) = 0.09 to 69.0]. In GlyRα3–/– mice, a 
significant interaction (P < 0.05) was found only for 60 
minutes [F(1,6) = 0.003 to 5.9]. The MPE was significant 
in wild-type and GlyRα3–/– mice [ANOVA followed by 
Bonferroni post-hoc test, F(3,30) = 24.7; ***P < 0.001, for 
2,6-DTBP versus vehicle]. No significant difference was 
found between 2,6-DTBP–treated wild-type and GlyRα3–/– 
mice (P = 0.55).
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decay time kinetics by 23.5% ± 7.5% (P < 0.01, paired t test). Applica-
tion of vehicle instead of 2,6-DTBP did not significantly change Gly-
IPSC amplitudes or decay time constants (data not shown).
Antihyperalgesic activity of 2,6-DTBP in behavioral models of 
pain. Finally, we investigated whether the modulatory effects 
of 2,6-DTBP on GlyRs translate to antihyperalgesic activity in 
inflammatory pain in vivo. To this end, we again induced inflam-
matory hyperalgesia in mice through subcutaneous injection of 
zymosan A and tested the effects of 2,6-DTBP on mechanical 
and heat hyperalgesia 48 hours after zymosan A injection (i.e., 
when central sensitization had reached its maximum; ref. 34). 2,6-
DTBP significantly reduced mechanical and heat hyperalgesia 
with a maximum response occurring 30 to 60 minutes after drug 
administration (Figure 7, A and B). 2,6-DTBP reversed mechanical 
and heat hyperalgesia at all the time points examined (P < 0.05, 
2-way repeated-measures ANOVA), whereas vehicle did not elicit 
significant effects. Consistent with our finding that phosphoryla-
tion was required to render GlyRs sensitive to 2,6-DTBP, we found 
that 2,6-DTBP had no analgesic effects against acute nociceptive 
stimuli (pin prick) in naive mice (withdrawal responses changed 
from 89% ± 6% to 92% ± 3% 30–90 minutes after 2,6-DTBP, 
P = 0.48, paired t test, n = 6) (Supplemental Figure 5A). To exclude 
possible confounding effects of 2,6-DTBP on locomotor activity, 
motor coordination, and muscle strength, we tested the effects 
of 2,6-DTBP on locomotion in an open-field arena, in the accel-
erating rotarod test and in the horizontal wire test. No significant 
effects were observed (Supplemental Figure 5, B–D).
To determine the contribution of α3GlyRs to 2,6-DTBP–
induced analgesia, we compared the antihyperalgesic effects of 
2,6-DTBP in wild-type and GlyRα3–/– mice in different pain models 
(Figure 7, C and D). We first address inflammatory hyperalgesia. 
Because previous studies have shown that GlyRα3–/– mice recover 
quickly from zymosan A–induced hypersensitivity (6), we switched 
to Complete Freund’s Adjuvant (CFA), which causes more pro-
longed hyperalgesia, and tested the effects of 2,6-DTBP at an early 
time point (48 hours) after CFA injection. Wild-type and GlyRα3–/– 
mice did not significantly differ in their mechanical paw-withdraw-
al thresholds (PWTs) at this time point and at baseline (Figure 7C). 
However, heat hyperalgesia in inflamed GlyRα3–/– mice was much 
less pronounced than in wild-type mice, precluding a quantitative 
comparison of antihyperalgesia by 2,6-DTBP in inflamed wild-type 
and GlyRα3–/– mice (Supplemental Figure 6). We therefore focused 
on mechanical hyperalgesia, which is also more relevant to chron-
ic pain in human patients (35). 2,6-DTBP significantly reduced 
mechanical hyperalgesia in wild-type mice by 44.3% ± 5.2% (Fig-
ure 7C). In GlyRα3–/– mice, this effect was reduced to 16.0% ± 6.2%, 
indicating that about two thirds of the 2,6-DTBP–evoked analgesia 
came from an interaction with α3GlyRs.
Previous work from our group suggested that phosphorylation 
and inhibition of GlyR α3 contributes to inflammatory but not to 
neuropathic hyperalgesia (36), while others have shown that 2,6-
DTBP still alleviated neuropathic hyperalgesia (37). We therefore 
investigated whether the antihyperalgesic effects of 2,6-DTBP 
in neuropathic pain also depended on GlyR α3. To this end, we 
examined the effects of 2,6-DTBP on neuropathic hyperalgesia 
in wild-type and GlyRα3–/– mice. Neuropathic hyperalgesia was 
induced by applying a chronic constriction injury (CCI) of the 
paired t test) but had no significant effect on the amplitudes (+8% 
± 10% of amplitudes during PGE2, P = 0.37, n = 12, paired t test) 
(Figure 5, A and D). Analyses of the charge transfer occurring dur-
ing Gly-IPSCs revealed that the prolongation of the decay time 
by 2,6-DTBP fully compensated for the reduction of Gly-IPSC 
amplitudes by PGE2. The change in IPSC charge transfer during 
PGE2 relative to control was –33% ± 5% (P < 0.001, paired t test, 
n = 12). In the additional presence of 2,6-DTBP, the total charge 
transfer increased to 108% ± 18% of control (n = 12). Superfusion 
of vehicle (0.1% DMSO) had no effect on either the amplitudes or 
decay kinetics of Gly-IPSCs (8.5% ± 7.5%, P = 0.27, and 19% ± 12%, 
P = 0.24, for amplitudes and decay time constants, respectively, 
n = 7). To verify the critical role of PKA-dependent phosphoryla-
tion in the priming of spinal cord slices by PGE2, we preincubat-
ed slices with the PKA inhibitor H89 (5 μM) (Figure 5, B and D). 
Under these conditions, PGE2 no longer sensitized GlyR to the 
potentiating actions of 2,6-DTBP (change in decay time constant 
by 2,6-DTBP: –1.8% ± 10.2%, P = 0.73, paired t test, n = 7). To fur-
ther prove that GlyR α3 was the relevant target of PKA-dependent 
phosphorylation, we performed experiments in slices taken from 
GlyRα3–/– mice (Figure 5, C and D). Before that, we tested whether 
the expression of GlyR α1 or GlyR β subunits changed following 
the loss of GlyR α3 expression. Real-time PCR analyses of lumbar 
spinal cord dorsal horn tissue from wild-type and GlyRα3–/– mice 
did not reveal significant changes. mRNA copy numbers rela-
tive to β-actin were 0.037 ± 0.017 versus 0.047 ± 0.012 for the α1 
subunit (Glra1; n = 6 for both groups, P = 0.28, unpaired t test), 
and 0.021 ± 0.009 versus 0.021 ± 0.004 for the β subunit (Glrb; 
n = 6 for both groups, P = 0.99, unpaired t test) in wild-type ver-
sus GlyRα3–/– mice, respectively. These data are consistent with 
unchanged expression and distribution of the GlyR α1 protein in 
the dorsal horn of GlyRα3–/– mice reported previously (Supple-
mental Figure 1 in ref. 6). Since the VGAT::ChR2 transgene had 
not been crossed into GlyRα3–/– mice, we evoked glycinergic IPSCs 
in these experiments by electrical field stimulation rather than 
through optogenetic stimulation. In GlyRα3–/– mice, PGE2 failed to 
render Gly-IPSCs susceptible to modulation by 2,6-DTBP (change 
in decay time constant induced by 2,6-DTBP: 1.2% ± 8.1% versus 
control, P = 0.74, paired t test, n = 12). Because the GlyRα3–/– mice 
lacked the VGAT::ChR2 transgene, the presence or absence of 
photocurrents could not be used to distinguish between inhibi-
tory and excitatory neurons. Nevertheless, we expect that at least 
half of these recordings were made from excitatory neurons (see 
also ref. 32). Taken together, these results suggest that both PKA 
inhibition and the absence of GlyR α3 prevented the priming effect 
of PGE2 on GlyRs, supporting that 2,6-DTBP potentiates synaptic 
GlyRs in a phosphorylation state–dependent manner.
In order to show that this priming also occurred in vivo in 
response to peripheral inflammation, we studied the effects of 
2,6-DTBP on Gly-IPSCs in slices prepared from five mice with an 
inflamed hindpaw (Figure 6). Inflammation was induced by subcu-
taneous injection of zymosan A into the left hindpaw (33), and the 
development of inflammatory hyperalgesia was confirmed by moni-
toring mechanical response thresholds. Application of 2,6-DTBP did 
not significantly alter the Gly-IPSC amplitudes (+3.6% ± 9.7% ver-
sus control amplitudes, P = 0.72, paired t test) or rise times (+13.5% 
± 3.8%, P = 0.09, paired t test). However, it significantly increased 
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lular regions and for heteromeric Cys-loop ion channels are still 
lacking. However, our homology modeling data (Figure 3H) sug-
gest that F388 lies in the so-called MA stretch, i.e., in a region that 
can influence some biophysical properties of ion channels (25). A 
comparison of the models of the α3-α3-α3 and α3-β-α3 interfaces 
suggests that the volume of the β subunit MA stretch is consider-
ably larger than that of the α3 subunit (by approximately 14,500 Å3, 
Supplemental Figure 8). Together with the functional data, these 
analyses suggest that, in homomeric α3GlyRs, all five potential 
binding sites are accessible to 2,6-DTBP, whereas the presence of β 
subunits in the receptor complex decreases not only the number of 
acceptor sites but also renders the acceptor sites within the α sub-
units less accessible to 2,6-DTBP (at least as long as the receptors 
are in the nonphosphorylated state). An unexpected finding was 
that the susceptibility of modulation by 2,6-DTBP of heteromeric 
α3βGlyRs was restored by phosphorylation of (or introduction of 
phosphomimetic mutations in) the α3 subunit at S346. This obser-
vation suggests a phosphorylation-induced conformational change 
in the α3 subunit permitting modulation of α3βGlyRs by 2,6-DTBP 
(Supplemental Figure 9).
Does modulation of GlyRs contribute to analgesic actions of 
2,6-DTBP? 2,6-DTBP not only potentiates GlyRs but also inhib-
its hyperpolarization and HCN ion channels (37), in particular 
HCN1 channels, which are expressed in peripheral nociceptors 
and contribute to pain sensitization (39). In addition, antioxidant 
properties of 2,6-DTBP (40, 41) may directly or indirectly (e.g., via 
inhibition of the T-type Ca2+ channel, ref. 42) contribute to anti-
hyperalgesia. Our finding that the analgesic effects of 2,6-DTBP 
in mice with inflamed paws were reduced by about two thirds in 
GlyRα3–/– mice indicates that α3GlyRs contribute significantly to 
the analgesic action of 2,6-DTBP. In line with a previous report 
(37), we found that 2,6-DTBP was active not only against inflam-
matory pain but also against neuropathic pain caused by periph-
eral nerve damage. Analgesia against the latter was, however, not 
diminished in GlyRα3–/– mice, consistent with our previous data 
that suggested that phosphorylation of α3GlyRs does not contrib-
ute to neuropathic hyperalgesia (36).
In addition to strychnine-sensitive GlyRs, spinal GABAARs 
constitute another target that might allow restoring proper synaptic 
inhibition in the spinal cord during chronic pain states. GABAARs 
offer plenty of opportunities for pharmacological interventions, 
but currently available drugs targeting GABAARs do not exert clini-
cally relevant analgesia, mainly because of dose-limiting sedative 
effects (43). Targeting GlyRs offers the advantage that glycinergic 
innervation is largely restricted to the hindbrain and spinal cord, 
and almost completely spares the forebrain, where most of the 
unwanted actions of GABAergic drugs originate. Consistent with 
this concept, 2,6-DTBP apparently lacks effects on locomotor 
activity, motor coordination, and muscle strength, which are typi-
cal side effects of classical GABAergic drugs such as the benzodiaz-
epines. It is likely that both the low abundance of glycinergic inner-
vation in the forebrain and specific modulation of phosphorylated 
GlyRs contribute to this favorable profile.
2,6-DTBP not only showed a preference for GlyRs over 
GABAARs but also preferred the low-abundance α3GlyRs over 
the much more prevalent α1GlyRs; the other two GlyR isoforms 
(α2 and α4GlyRs) are less relevant as drug targets. α2GlyRs are 
left sciatic nerve (38). 2,6-DTBP reduced hyperalgesia in both 
wild-type and GlyRα3–/– mice to very similar degrees (Figure 7D, 
see also Supplemental Figure 7). The maximum antihyperalgesic 
responses, which were reached between 30 and 60 minutes after 
the drug administration, were not significantly different between 
wild-type and GlyRα3–/– mice (wild-type: 46.1% ± 4.6% versus 
GlyRα3–/–: 41.0% ± 4.7% of maximum possible effect [MPE]), 
indicating that antihyperalgesic actions against neuropathic pain 
occurred independently of GlyR α3. Taken together, these findings 
indicate that dorsal horn GlyRs are modulated by 2,6-DTBP in a 
phosphorylation state–dependent manner and that this modula-
tion is particularly relevant for inflammatory hyperalgesia. 2,6-
DTBP also exerts antihyperalgesia against neuropathic pain, but 
these actions occurred through targets different from α3GlyRs, 
possibly involving other GlyRs (16) or hyperpolarization-activated 
cyclic nucleotide–gated (HCN) channels (37).
Discussion
Our results establish the nonanesthetic propofol derivative 2,6-
DTBP as an efficacious enhancer of glycinergic inhibition in the 
superficial spinal dorsal horn, a key area for central pain control. 
2,6-DTBP not only spared GABAARs, but also was particularly effec-
tive at α3-containing GlyRs, which are abundant in the spinal termi-
nation area of nociceptive nerve fibers. While homomeric α3GlyRs 
were potentiated by 2,6-DTBP under basal conditions, heteromeric 
(β subunit–containing) GlyRs, which prevail at postsynaptic sites, 
were potentiated only in a phosphorylated (primed) state. In line 
with these results, 2,6-DTBP potentiated synaptic GlyR receptor 
currents in spinal cord slices only after priming with the inflamma-
tory mediator PGE2, or in slices that were obtained from mice with 
peripheral inflammation. The phosphorylation site responsible for 
this priming effect is present in α3GlyRs but is absent in α1GlyRs.
Mechanisms and sites for modulation. When homomeric GlyR 
channels expressed in HEK293T cells were investigated, 2,6-
DTBP shifted the glycine concentration response curve to the left. 
This leftward shift corresponds well with the increase in channel-
open probability observed in our single-channel recording experi-
ments. In spinal cord slices primed with PGE2, 2,6-DTBP pro-
longed the decay of synaptic GlyR currents without altering their 
amplitudes, consistent with the observed shift in the glycine con-
centration-response curve. In terms of gross glycinergic inhibition 
(measured as total charge transfer), this prolongation of the decay 
time course at least partially counteracted the reduction in the 
amplitude of glycinergic responses seen in the presence of PGE2.
Our present results indicate that modulation of α3GlyRs by 2,6-
DTBP depends on a single phenylalanine residue (F388), which is 
also required for the modulation of homomeric glycine receptors 
by propofol, the parent compound of 2,6-DTBP (21). Up to now, 
a potential role in this process of the β subunit and of posttransla-
tional modifications has remained unclear. In the present study, 
we show that heteromeric α3βGlyRs (in their nonphosphorylated 
state) are much less susceptible to modulation by 2,6-DTBP. This 
is consistent with the presence of an isoleucine residue instead of 
phenylalanine at the respective position in the β subunit (I443), and 
may in addition suggest that the presence of the β subunit prevents 
2,6-DTBP from accessing its binding site in the α subunit (compare 
Supplemental Figure 3). Crystal structures for TM3-TM4 intracel-
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Methods
Reagents. 2,6-DTBP and PTX were obtained from Sigma-Aldrich. PGE2, 
bicuculline, strychnine, QX-314, and H89-dihydrochloride were pur-
chased from Tocris. D-APV and CNQX were obtained from ANAWA. 2,6-
DTBP and PGE2 were dissolved in DMSO at 100 μM and kept at –20°C.
Electrophysiology on recombinant GlyRs. Recombinant GlyRs were 
transiently expressed in HEK293T cells (originally obtained from 
ATCC-LGC Standards GmbH) using Lipofectamine LTX (Invitrogen). 
One microgram of DNA per 35-mm dish was used for transfection of α1 
and α3 subunits together with 0.5 μg of an EGFP expression plasmid to 
allow identification of the transfected cells. In experiments on αβ het-
eromeric GlyRs, plasmids encoding α and β subunits were transfected 
at a ratio of 1:15. To confirm the expression of heteromeric GlyRs, PTX 
sensitivity was routinely monitored (ref. 7 and Supplemental Figure 1). 
All recordings were made 18 to 36 hours after transfection. The cDNAs 
encoding the GlyRs have been described previously (49). Mutations 
were inserted using the QuickChange site-directed mutagenesis kit 
(Agilent Technologies) or by an external supplier (Mutagenex). Proper 
sequences of all constructs were confirmed by full-length sequencing.
Glycine-evoked whole-cell currents were recorded at room tem-
perature (20°C–24°C) at a holding potential of –60 mV using the patch-
clamp technique. Patch electrodes (3–4 MΩ) were pulled from borosili-
cate glass and filled with (in mM): 120 CsCl, 10 EGTA, 10 HEPES (pH 
7.4), 4 MgCl2, 0.5 GTP, and 2 ATP. The external solution contained (in 
mM) 150 NaCl, 10 KCl, 2.0 CaCl2, 1.0 MgCl2, 10 HEPES (pH 7.4), and 
10 glucose. Recordings were performed with a HEKA EPC-7 ampli-
fier and Patch Master v2.11 software (HEKA Elektronik). Glycine was 
applied via a manually controlled gravity-fed application system with 
an inner diameter of 200 μm positioned 50 to 120 μm from the record-
ed cell. Glycine EC10 values for each GlyR studied were obtained exper-
imentally after successive application of 1, 10, 30, 60, 100, 200, 500, 
and 1,000 μM glycine (see also Supplemental Table 1). The concentra-
tion-response curve parameters (EC50 and Hill coefficient [nH]) were 
obtained from the curve fits of normalized concentration-response to 
the equation Igly = Imax[gly]nH/([gly]nH + [EC50]nH). The mean maximal 
current (Imax) was determined by applying 1 mM glycine. 2,6-DTBP was 
first dissolved in DMSO (100%) at a concentration of 100 mM and 
subsequently diluted in several steps to the final concentration on the 
day of the experiment. Before use, solutions were vigorously shaken 
for 60 minutes. The maximum DMSO concentration was 0.3%. 2,6-
DTBP was co-applied with glycine, without pre-application. Single-
channel recordings from transfected cells were done as described (19, 
28). All recordings were performed in the cell-attached configuration 
at 19°C–21°C with thick-walled borosilicate glass pipettes (final resis-
tance of 10–15 MΩ). The extracellular solution contained (in mM): 20 
Na-gluconate, 102.7 NaCl, 2 KCl, 2 CaCl2, 1.2 MgCl2, 10 HEPES, 20 
TEA-Cl, 15 sucrose, and 14 glucose, pH 7.4. The pipette solution was 
filled with the same extracellular solution but containing glycine (100–
150 μM) or glycine plus 2,6-DTBP (10 μM). Single-channel currents 
were recorded with an RK-400 patch-clamp amplifier (Bio-Logic) at a 
pipette potential of +60 mV. Recordings were prefiltered at 10 kHz and 
were digitized to a computer using a Digidata 1400 (Molecular Devic-
es) and pClamp 10 (Axon Instruments).
Molecular modeling and docking. Because most of the structural 
data available on GlyRs do not include the TM3-TM4 intracellular 
domain, we modeled the α3 subunit as previously described for the 
α1GlyR (50) using the ab initio technique with QUARK (51). The full-
mainly expressed during prenatal and early postnatal develop-
ment (7), and the gene encoding the α4 subunit is a pseudogene 
in humans (9, 44). Compared with α1GlyRs, which are found 
throughout most parts of the spinal cord and hindbrain, α3GlyRs 
are expressed in a much more spatially restricted manner. In the 
spinal cord, GlyR α3 subunit expression is limited to the super-
ficial layers of the dorsal horn (6), while at supraspinal sites, 
α3GlyR expression is generally weak and found only in a few 
sites, such the retina (45), cerebellum, and hippocampus (46). 
The preferential potentiation of α3GlyRs may thus help avoiding 
unwanted effects such as strong muscle relaxation.
An additional level of specificity comes from the dependence 
of modulation of synaptic GlyRs on prior phosphorylation. Most 
postsynaptic GlyRs are heteromers containing, in addition to 
α subunits, β subunits, which anchor the channel complexes to 
postsynaptic sites. Our experiments revealed that, under resting 
(nonphosphorylated) conditions, heteromeric α3βGlyRs were 
much less sensitive to modulation by 2,6-DTBP than homomeric 
receptors. However, introduction of a phosphomimetic amino 
acid exchange in the α3 subunit of recombinant α3βGlyRs restored 
susceptibility to modulation by 2,6-DTBP. Accordingly, native 
postsynaptic GlyRs of the spinal dorsal horn were only modulat-
ed after priming through pretreatment of spinal cord slices with 
PGE2, which leads to PKA-dependent phosphorylation of α3GlyRs, 
or, when slices were taken from mice with an inflamed hindpaw. 
Importantly, the consensus site for PKA-dependent phosphoryla-
tion of GlyR α3 subunits is missing from the α1 subunit, introduc-
ing again an additional level of specificity. The absence of this site 
in GlyR α1 subunits may explain why we did not find effects of 2,6-
DTBP on muscle strength, even though GlyRs effectively control 
motoneuron excitability.
Recordings of synaptic GlyR currents in slices obtained from 
naive (noninflamed) mice were not modulated by 2,6-DTBP, 
suggesting that homomeric α3GlyRs lacking GlyR β subunits do 
not make a measurable contribution to synaptic inhibition in the 
dorsal horn. However, homomeric receptors may be present at 
extrasynaptic sites where they would mediate tonic currents. In 
line with a previous report (31), we found tonic currents only in a 
small portion of cells, and these currents were of very small (≤5 
pA) amplitudes. In certain areas of the brainstem, homomeric 
α1GlyRs have been reported to be present in presynaptic terminals 
where they control transmitter release (47, 48). The lack of modu-
lation of glycinergic synaptic currents by 2,6-DTBP suggests that 
such homomeric presynaptic GlyRs are not present in the superfi-
cial dorsal horn. However, it is possible that such receptors exist at 
other sites and that interaction with these receptors might cause 
effects of 2,6-DTBP on behaviors of mice not studied here.
In summary, our results describe a phosphorylation state–
dependent interaction of a propofol derivative with inflammation-
primed synaptic GlyRs in the spinal dorsal horn. Reduced analgesic 
effects in GlyRα3–/– mice suggest that this phosphorylation-depen-
dent potentiation contributes to the analgesic effects of 2,6-DTBP 
against inflammatory pain (Supplemental Figure 10). These results 
provide direct evidence that diminished inhibitory pain control in 
the spinal cord can be restored by positive allosteric modulation of 
GlyRs, and may pave the path for the generation of new spinally 
acting analgesics with limited supraspinal side effects.
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were kept in oxygenated (95% O2/5% CO2) artificial cerebrospinal 
fluid (aCSF) containing (in mM): 120 NaCl, 5 HEPES, 26 NaHCO3, 1.25 
NaH2PO4, 2.5 KCl, 2 CaCl2, 1 MgCl2, and 10 glucose (pH 7.35) at 35°C 
for 1 hour. Slices were then transferred to the recording chamber, which 
was continuously perfused with oxygenated aCSF at a flow rate of 1.5 
to 2.0 ml/min. Superficial dorsal horn neurons were visually identified 
using infrared gradient contrast equipment. Recordings in neurons 
obtained from VGAT::ChR2 mice were made from excitatory neurons 
identified by the absence of a light-induced photocurrent. Recordings 
in neurons from GlyRα3–/– mice were made from randomly chosen lam-
ina II neurons. Whole-cell patch-clamp recordings were made at room 
temperature at a holding potential of –60 mV using a HEKA EPC-10 
amplifier and PatchMaster v2.11 software (HEKA Elektronik). Patch 
pipettes (3.5–4.5 MΩ) were filled with internal solution containing: (in 
mM) 120 CsCl, 10 EGTA, 4 MgCl2, 0.5 GTP, 2 ATP, and 10 HEPES (pH 
7.30, adjusted with CsOH). QX-314 (5 mM) was added to block voltage-
activated Na+ currents in the recorded cell. Once the whole-cell mode 
was established, the cell was allowed to stabilize for 2 to 5 minutes. 
Light-evoked IPSCs were elicited by whole-field blue light (473 nm) 
illumination (4-ms duration) at a frequency of 0.1 Hz. Glycinergic or 
GABAergic light-evoked IPSCs were isolated using bicuculline (10 
μM) or strychnine (1 μM), respectively. In GlyRα3–/– mice, glycinergic 
IPSCs were evoked by electrical field stimulation at a frequency of 0.1 
Hz (100 μs, 3–30 V) using a glass electrode (5–7 MΩ) filled with stan-
dard extracellular solution and placed about 50 μm from the recorded 
neuron (6). Gly-IPSCs were isolated using CNQX (5 μM), D-APV (50 
μM), and bicuculline (10 μM). After 3 to 5 minutes of baseline record-
ing, 2,6-DTBP (100 μM) or PGE2 (1 μM) was added to the bath solution 
for 8 to 10 minutes. To examine the role of PKA-dependent phosphory-
lation, slices were continuously superfused with H89 (5 μM). At the end 
of each recording, strychnine (1 μM) or bicuculline (10 μM) was added 
to confirm the glycinergic or GABAergic nature of the recorded IPSCs.
Animals. Breeding pairs of GlyRα3−/− mice (6) were provided by 
Robert J. Harvey, Ulrike Müller, and Heinrich Betz (all at the Max Planck 
Institute for Brain Research, Frankfurt, Germany). VGAT::ChR2-
eYFP mice (29) were provided by Guoping Feng, McGovern Institute 
for Brain Research at MIT, Cambridge, Massachusetts, USA. GlyRα3−/− 
mice and VGAT::ChR2-eYFP BAC transgenic mice were maintained 
on a C57BL/6 background. All mice were group housed with a stan-
dard 12-hour light/dark cycle and food and water available ad libitum.
Behavioral tests. Antihyperalgesic properties of 2,6-DTBP (90 mg/
kg i.p.) were studied in 7- to 12-week-old mice subjected to the zymo-
san A and CFA models of inflammatory hyperalgesia (6, 33). Mice 
were injected subcutaneously with either zymosan A (0.06 mg in 20 μl 
saline) or CFA (1:2 diluted in saline) into the plantar side of the left hind 
paw. To study the effects of 2,6-DTBP on neuropathic pain, mice were 
subjected to the CCI (38). In brief, three loose (5-0 silk) ligatures were 
put around the left sciatic nerve proximal to the trifurcation. Mice that 
showed signs of paralysis or did not develop significant hypersensitivity 
were excluded from subsequent experiments. Mechanical and thermal 
nociceptive sensitivities were determined using electronic von Frey 
filaments and the plantar test, respectively. 2,6-DTBP was dispersed 
in saline/0.05% Tween 20 (vehicle), sonicated on ice, and injected i.p. 
(see also refs. 37 and 58). Sensitivities of the ipsilateral (inflamed or 
nerve-injured) paw and the contralateral control paw were measured 
alternately and at least four measurements were taken per mouse for 
all time points. Antihyperalgesia was quantified for a time interval of 
length GlyR α3 subunit was created by homology modeling using Glu-
Cl [PDB: 2RIF] (27) as the template in Modeller 9v13 (52). Additional 
refinement was performed using the α1GlyR-GLIC structure (28). The 
final model was obtained after energy minimization with a conjugate 
gradient protocol in the software MacroModel (version 9.9, Schröding-
er, LLC). The resulting helical conformation of the C-terminal region 
of the TM3-TM4 intracellular domain (MA stretch) of α3GlyR was 
similar to the recently resolved structure for the 5-HT3 receptor (53) 
and to the proposed TM3-TM4 intracellular domain of the GlyR α1 
subunit (50). Docking of the protein and ligand was performed using 
the model of the α3 subunit and the 2,6-DTBP structure available in 
the ZINC database [ID: ZINC01681254] (54). An initial complex was 
created with Glide (version 5.9, Schrödinger, LLC) using a receptor 
grid centered on residue F388 of α3GlyR. Analysis of the interface 
by the same software, including structural and energetic parameters, 
generated a docking score (55). Additionally, a second energy calcula-
tion, MM-GBSA, was performed using Prime (version 3.2, Schröding-
er, LLC) to predict a theoretical ΔGbind. Taken together, the docking 
score and ΔGbind improved the description of the interaction between 
α3GlyR and 2,6-DTBP. The β subunit was modeled using the α1GlyR 
model (50), and interfaces α3-α3 and α3-β were constructed based on 
the α1GlyR pentamer [PDB: 2M6B] (56). The GlyR α3 F388 mutant 
was created using BioLuminate (version 1.1, Schrödinger, LLC) and 
consequent dockings were performed under the same conditions as 
those described above. All images were created using PyMol (version 
1.5, DeLano Scientific LLC).
In situ PLA. PGE2-induced phosphorylation of the GlyR α3 sub-
unit was analyzed using the in situ PLA (26). cDNAs encoding GlyR 
α3 and EP2, or GlyR α3(S346A) and EP2, were transfected into 
HEK293T cells grown on poly-lysine–coated coverslips using the PEI 
(polyethylenimine) method. Two days after transfection, cells were 
incubated in 1 μM PGE2 for 30 minutes. After fixation in 4% parafor-
maldehyde for 30 minutes, cells were permeabilized in 0.2% Triton/
PBS. Phosphorylation of α3GlyR was tested with the in situ PLA using 
antibodies directed against α3GlyR (1:50, Millipore, catalog AB15014) 
and phosphoserine (1:5, Millipore, catalog 05-1000X). The cells were 
incubated with the primary antibodies overnight and processed for 
in situ PLA using the Duolink kit (Sigma-Aldrich) as described previ-
ously (57). Images (as z-stack with a 0.8-μm z-interval) were obtained 
with a Zeiss 510 Meta confocal laser scanning microscope using a 
Zeiss 100× plan-fluar objective (N.A. = 1.4). Quantification of in situ 
PLA signals was performed by counting individual PLA fluorescence 
spots using ImageJ (NIH). The optical sections of each image stack 
were summed into one image, median filtered (r = 1.0 pixels), and 
subjected to automated spot detection. The number of spots was then 
normalized to the cell area.
RT-PCR. Six lumbar spinal cords were rapidly removed from 
euthanized adult wild-type and GlyRα3–/– mice. mRNA was tran-
scribed into cDNA using the QuantiTect Reverse Transcription Kit 
(QIAGEN, catalog 205311). Expression levels of GlyR α1 and GlyR β 
subunits relative to β-actin were determined using commercially avail-
able detection assays (Integrated DNA Technologies, catalog number 
Mm.PT.58.9052470 for Glra1, Mm.PT.58.29236025 for Glrb, and 
Mm.PT.58.33257376.gs for Actb).
Recordings in spinal cord slices. Transverse spinal cord slices were 
prepared from 2- to 3-week-old VGAT::ChR2-eYFP mice (29) and GlyR 
α3–deficient (GlyRα3–/–) mice (6) of either sex. Slices (400 μm thick) 
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30 to 60 (for zymosan A model and CCI) or 60 to 90 minutes (for CFA) 
after drug injection when the drug effect was maximal, and expressed 
as percentage of maximum possible analgesic effect (MPE). MPE 
= (Rpost-drug – Rpre-drug)/(Rbaseline – Rpre-drug) × 100, where R is the average 
response latency or threshold under baseline condition (Rbaseline), after 
induction of inflammation but before drug injection (Rpre-drug), and after 
drug injection (Rpost-drug). Accelerating rotarod performance (from 4 to 
40 rpm) of wild-type mice was measured 60 minutes after the admin-
istration of 2,6-DTBP or vehicle. Each mouse was tested three times. 
Mice were trained with 2 different training sessions on 2 consecutive 
days before testing. The locomotor activity assays were performed 
during the light phase of the day-night cycle. The animals were placed 
in individual circular enclosures (20-cm diameter) equipped with 4 
photocells. The locomotor activity was expressed as the total number 
of photocell interruptions recorded in a period of 6 hours immediately 
after drug administration. The horizontal wire test (59) was performed 
to assess potential muscle relaxation. Mice were placed forepaws-first 
onto a 15-cm metal wire and scored according to whether or not they 
were able to grasp the wire with their hindpaws. Acute pain was mea-
sured in the so-called pin-prick test using an injection needle applied to 
the plantar surface of the hindpaw without breaking the skin. The num-
ber of paw withdrawals out of three trials was calculated as a percent-
age for each time point. The experimenter was blind to mouse genotype 
and drug treatment. Special care was taken to ensure equal numbers of 
age-matched male and female mice in all behavioral experiments.
Statistics. All data are displayed as the mean ± SEM. Statistical 
comparisons were made with 2-tailed paired or unpaired t tests or with 
ANOVA or repeated measures ANOVA followed by appropriate post-hoc 
tests. P values less than 0.05 were considered statistically significant.
Study approval. Permission for and approval of the animal experi-
ments was obtained from the Tierversuchskommission of the canton of 
Zurich, Zurich, Switzerland (license numbers 135/2009 and 126/2012).
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